The osteoarthritis therapeutics market is projected to reach USD 11.0 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025. The presence of a large geriatric and target patient population and the improving healthcare infrastructure in several APAC countries are expected to offer growth opportunities in the market during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209565994
“Knee osteoarthritis therapeutics is expected to hold the largest share of the osteoarthritis therapeutics market, by anatomy in 2020.”
Based on anatomy, the market is segmented into knee, hip, hand, and small-joint osteoarthritis therapeutics. Knee osteoarthritis therapeutics is the largest and the fastest-growing segment in this market. This can primarily be attributed to the high incidence of knee osteoarthritis.
“Viscosupplementation agents is expected to hold the largest share of the osteoarthritis therapeutics market, in 2020.”
Based on drug type, the market is classified as, viscosupplementation agents, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids. The analgesics segment is subsegmented into duloxetine and acetaminophen, while the NSAIDs segment is subsegmented into naproxen, aspirin, diclofenac, ibuprofen, and other NSAIDs. The viscosupplementation agents segment accounted for the largest share of the osteoarthritis therapeutics market in 2019. The rising incidence of knee osteoarthritis is the major factor driving the growth of this segment. Viscosupplementation effectively eases the pain of osteoarthritis through injections that fill up the joint’s synovial fluid, thus offering better lubrication of the joints.
“Parental route is expected to hold the largest share of the osteoarthritis therapeutics market in 2020.”
On the basis of route of administration, the osteoarthritis therapeutics market has been segmented into oral, topical, and parenteral routes. The parenteral route accounted for the largest share of this market in 2019 and is estimated to grow at the highest CAGR during the forecast period. This can be attributed to the wide adoption of the parenteral route for administering osteoarthritis therapeutics owing to the ease of administration and the better pharmacokinetics and pharmacodynamics, resulting in better patient compliance.
“Hospital pharmacies segment commanded the largest share of the osteoarthritis therapeutics market in 2020.”
Based on the distribution channel, the osteoarthritis therapeutics market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. In 2019, hospital pharmacies accounted for the largest share of this market because of the high volume of patients visiting hospitals for osteoarthritis treatments and the wide range of osteoarthritis therapeutics available in these pharmacies. Reimbursements can also be claimed easily on hospital pharmacy purchases, which is another important draw.
“Prescription drugs segment commanded the largest share of the osteoarthritis therapeutics market in 2020.”
Based on the purchasing pattern, the osteoarthritis therapeutics market is segmented into OTC and prescription drugs. In 2019, the prescription drugs segment accounted for a larger share of this market as most osteoarthritis therapeutics (viscosupplementation agents and corticosteroids) are only available on prescription.
“Europe commanded the largest share of the osteoarthritis therapeutics market in 2020.”
On the basis of region, the osteoarthritis therapeutics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, Europe commanded the largest share of the osteoarthritis therapeutics market. The large share of this market segment can be attributed to the rising incidence of osteoarthritis, rising geriatric population, and increasing obesity rates in several European countries, coupled with the rising number of injuries due to sports and road accidents.
The major players operating in this market are Sanofi (France), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Bayer AG (Germany), Abbott (US), Pfizer, Inc. (US), Eli Lilly (US), Anika Therapeutics, Inc. (US), Novartis AG (Switzerland), Ferring Pharmaceuticals (Switzerland), Bioventus (US), Zimmer Biomet Holdings, Inc. (US), Fidia Farmaceutici s.p.a. (Italy), Flexion Therapeutics, Inc. (US), Pharmed Limited (India), Virchow Biotech (India), Kitov Pharmaceuticals Ltd. (Israel), Assertio Therapeutics, Inc. (US), Atnahs (UK), Almatica Pharma LLC (US), OrthogenRx (US), LABRHA (France), Hanmi Pharm. Co., Ltd. (Korea), and Laboratorio Reig Jofre (Spain).
US EVERY YEAR FOR THEIR
HOME ❯ TOP MARKET REPORTS ❯ OSTEOARTHRITIS THERAPEUTICS
Osteoarthritis Therapeutics Market by Anatomy (Knee, Hand), Drug
Type (NSAIDs, Analgesics, Corticosteroids), Route of Administration
(Parenteral), Distribution Channel (Hospital Pharmacies),Purchasing
Pattern (Prescription Drugs) - Global Forecast to 2025
[201 Pages Report] The osteoarthritis therapeutics market is projected to reach USD 11.0 billion
by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025. The presence of a
large geriatric and target patient population and the improving healthcare infrastructure in several
APAC countries are expected to offer growth opportunities in the market during the forecast period.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID -19 Impact on the Osteoarthritis Therapeutics Market
The market for osteoarthritis therapeutics is anticipated to be marginally affected due to the
outbreak of COVID-19. Among drug types, the use of corticosteroids has reduced. Although there is
no evidence to suggest that corticosteroid injections lead to a substantial increase in the risk of
infection, there is a possible reduction in the immune response for up to a few weeks following the
procedure. While this risk is extremely low, it needs to be considered when deciding to proceed with
It should also be noted that the WHO, in one of its guidelines for the management of severe acute
respiratory infection in patients with coronavirus, suggested avoiding systemic corticosteroids.
DRIVER: Rising government investments in cell-based research significant adoption of
Topical, oral, and parenteral pain medications are widely used to manage pain associated with
osteoarthritis. Although alternatives such as orthopedic braces are used as part of a